HK1173139A1 - Fluorinated derivatives of 3-hydroxypyridin-4-ones 3--4- - Google Patents

Fluorinated derivatives of 3-hydroxypyridin-4-ones 3--4-

Info

Publication number
HK1173139A1
HK1173139A1 HK12111353.4A HK12111353A HK1173139A1 HK 1173139 A1 HK1173139 A1 HK 1173139A1 HK 12111353 A HK12111353 A HK 12111353A HK 1173139 A1 HK1173139 A1 HK 1173139A1
Authority
HK
Hong Kong
Prior art keywords
hydroxypyridin
ones
fluorinated derivatives
fluorinated
derivatives
Prior art date
Application number
HK12111353.4A
Other languages
English (en)
Chinese (zh)
Inventor
Tim Fat Tam
Regis Leung-Toung
Yingsheng Wang
Yanqing Zhao
Tao Xin
Birenkumar Shah
Blaise Nzemba
Jolanta Maria Wodzinska
Maryna Premyslova
Original Assignee
Apotex Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43410413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1173139(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apotex Technologies Inc filed Critical Apotex Technologies Inc
Publication of HK1173139A1 publication Critical patent/HK1173139A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK12111353.4A 2009-07-03 2012-11-09 Fluorinated derivatives of 3-hydroxypyridin-4-ones 3--4- HK1173139A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22297909P 2009-07-03 2009-07-03
PCT/CA2010/001027 WO2011000104A1 (en) 2009-07-03 2010-07-05 Fluorinated derivatives of 3-hydroxypyridin-4-ones

Publications (1)

Publication Number Publication Date
HK1173139A1 true HK1173139A1 (en) 2013-05-10

Family

ID=43410413

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12111353.4A HK1173139A1 (en) 2009-07-03 2012-11-09 Fluorinated derivatives of 3-hydroxypyridin-4-ones 3--4-

Country Status (34)

Country Link
US (6) US9073865B2 (xx)
EP (1) EP2448922B1 (xx)
JP (1) JP5611339B2 (xx)
KR (1) KR101682966B1 (xx)
CN (2) CN102712591B (xx)
AU (1) AU2010268666B2 (xx)
BR (1) BR112012000079A2 (xx)
CA (1) CA2767130C (xx)
CL (1) CL2012000009A1 (xx)
CY (1) CY1115632T1 (xx)
DK (1) DK2448922T3 (xx)
EA (1) EA020976B1 (xx)
EC (1) ECSP12011648A (xx)
ES (1) ES2524342T3 (xx)
GE (1) GEP20146008B (xx)
HK (1) HK1173139A1 (xx)
HR (1) HRP20141051T1 (xx)
IL (1) IL217349A (xx)
MA (1) MA33985B1 (xx)
ME (1) ME01911B (xx)
MX (1) MX2012000247A (xx)
MY (1) MY163058A (xx)
NI (1) NI201200004A (xx)
NZ (1) NZ597893A (xx)
PE (1) PE20120924A1 (xx)
PL (1) PL2448922T3 (xx)
PT (1) PT2448922E (xx)
RS (1) RS53642B1 (xx)
SG (1) SG177462A1 (xx)
SI (1) SI2448922T1 (xx)
TN (1) TN2011000678A1 (xx)
UA (1) UA108076C2 (xx)
WO (1) WO2011000104A1 (xx)
ZA (1) ZA201200751B (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112552232B (zh) * 2020-12-16 2022-11-25 浙江工业大学 一种吡啶酮六位炔胺修饰衍生物及其制备方法与应用
CN115144480B (zh) * 2021-03-31 2023-11-28 成都倍特药业股份有限公司 一种从罗沙司他中间体中检测吗啉和/或四甲基甲烷二胺的方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918402A (en) 1958-07-29 1959-12-22 Dodge Chem Co Bactericidal-fungicidal compositions
NL300788A (xx) 1962-12-20
CA1095921A (en) 1976-08-02 1981-02-17 Thomas M. Brennan Preparation of gamma-pyrones
GB8308055D0 (en) 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
GB8308054D0 (en) 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
USRE34313E (en) 1983-09-23 1993-07-13 National Research Development Corporation Pharmaceutical compositions
GB8325496D0 (en) 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
GB8329043D0 (en) 1983-10-31 1983-11-30 Hider R C Pharmaceutical compositions
EP0336369A1 (en) 1988-04-04 1989-10-11 E.R. Squibb & Sons, Inc. 3-Acylamino-1-[[[(substituted sulfonyl)amino]carbonyl]amino]2-azetidinones
DE3826846A1 (de) * 1988-08-06 1990-02-08 Goedecke Ag Alkoxy-4(1h)-pyridon-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
JPH0714872B2 (ja) 1990-02-06 1995-02-22 昭和薬品化工株式会社 シロップ剤組成物
GB9100465D0 (en) 1991-01-09 1991-02-20 Hider Robert C Pharmaceutical compositions
US5624807A (en) 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
EP0620001A1 (en) 1993-04-16 1994-10-19 McNEIL-PPC, INC. Aqueous pharmaceutical suspension and process for preparation thereof
NZ276786A (en) * 1994-01-31 1998-05-27 Cultor Corp Synthesis of gamma-pyrones from a haloenone intermediate
JP2001508755A (ja) 1994-04-08 2001-07-03 ザ、プロクター、エンド、ギャンブル、カンパニー 哺乳動物でラジカルダメージを減少させるために鉄キレート化合物を用いる方法
WO1996003976A1 (en) 1994-08-01 1996-02-15 Kv Pharmaceutical Corporation Tastemasked liquid pharmaceutical delivery system
US5616621A (en) 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
JPH0925234A (ja) 1995-07-12 1997-01-28 Wakunaga Pharmaceut Co Ltd 脳疾患改善剤
PT768302E (pt) * 1995-09-29 2005-11-30 Novartis Ag Novas hidroxipiridinonas
US5763449A (en) 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
GB9711093D0 (en) * 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
EP1025858A4 (en) 1998-08-28 2009-03-11 Eisai R&D Man Co Ltd DRUGS WITH REDUCED BITTERNESS ETC.
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6133322A (en) 1998-10-29 2000-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6933104B1 (en) 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
IL130324A0 (en) 1999-06-07 2000-06-01 Yeda Res & Dev Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators
AUPQ262499A0 (en) 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
CA2313270C (en) 2000-06-30 2011-09-13 Apotex Inc. Use of deferiprone in treating and preventing iron-induced cardiac disease
JP2004535370A (ja) 2001-03-05 2004-11-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 味をマスクした液体製薬学的組成物
WO2003075910A1 (en) 2002-03-08 2003-09-18 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
MXPA04008720A (es) 2002-03-12 2004-12-06 Squibb Bristol Myers Co Suspension oral de sabor agradable y metodo.
US20040101521A1 (en) 2002-07-12 2004-05-27 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression
EP1565185A4 (en) 2002-11-07 2011-01-05 Technion Res & Dev Foundation NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
DE10336497B4 (de) 2003-08-08 2007-04-05 Freie Universität Berlin Substituierte Pyridine und ein Verfahren zur Herstellung von substituierten Pyridinen
WO2005117911A2 (en) 2004-05-06 2005-12-15 Cydex, Inc. Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
EP1755579A4 (en) 2004-05-24 2009-06-10 Univ New York METHOD FOR TREATING OR PREVENTING PATHOLOGICAL EFFECTS OF AN ACUTE INCREASE OF HYPERGLYCEMIA AND / OR ACUTE INCREASE IN FREE FATTY ACID FLUID
US9737511B2 (en) 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US7728038B2 (en) 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
US20060093630A1 (en) 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20070197469A1 (en) 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
KR20080104329A (ko) 2006-02-22 2008-12-02 아놀드 뮤니히 데페리프론의 이용 및 철의 세포 내 미스핸들링으로부터 비롯된 프리드리히 운동실조증의 치료 및/또는 예방 방법
US8026261B2 (en) 2007-03-28 2011-09-27 Apotex Technologies Inc. Fluorinated derivatives of deferiprone
GB0803019D0 (en) * 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds
DK2268282T3 (en) 2008-04-25 2014-11-24 Apotex Technologies Inc Liquid formulation of deferiprone with pleasant taste

Also Published As

Publication number Publication date
AU2010268666B2 (en) 2014-07-24
JP2012531468A (ja) 2012-12-10
TN2011000678A1 (en) 2013-05-24
ME01911B (me) 2014-12-20
US20150274665A1 (en) 2015-10-01
CN103601673A (zh) 2014-02-26
US9550733B2 (en) 2017-01-24
WO2011000104A1 (en) 2011-01-06
KR20120093822A (ko) 2012-08-23
IL217349A0 (en) 2012-02-29
MY163058A (en) 2017-08-15
PT2448922E (pt) 2014-12-02
DK2448922T3 (da) 2014-11-10
US9073865B2 (en) 2015-07-07
MA33985B1 (fr) 2013-02-01
EP2448922A4 (en) 2012-12-19
CA2767130C (en) 2017-08-22
EA020976B1 (ru) 2015-03-31
AU2010268666A1 (en) 2012-02-23
IL217349A (en) 2015-08-31
UA108076C2 (xx) 2015-03-25
CA2767130A1 (en) 2011-01-06
CN103601673B (zh) 2016-03-16
PE20120924A1 (es) 2012-08-19
US20170088518A1 (en) 2017-03-30
HRP20141051T1 (hr) 2014-12-19
SG177462A1 (en) 2012-02-28
US20120270882A1 (en) 2012-10-25
KR101682966B1 (ko) 2016-12-06
US9938240B2 (en) 2018-04-10
ECSP12011648A (es) 2012-07-31
MX2012000247A (es) 2012-03-26
US20160083346A1 (en) 2016-03-24
JP5611339B2 (ja) 2014-10-22
PL2448922T3 (pl) 2015-02-27
CY1115632T1 (el) 2017-01-04
US20150335626A1 (en) 2015-11-26
EA201270119A1 (ru) 2012-07-30
NZ597893A (en) 2013-01-25
BR112012000079A2 (pt) 2017-07-25
ZA201200751B (en) 2012-10-31
CN102712591B (zh) 2014-06-25
SI2448922T1 (sl) 2014-12-31
RS53642B1 (en) 2015-04-30
NI201200004A (es) 2013-06-12
GEP20146008B (en) 2014-01-10
ES2524342T3 (es) 2014-12-05
CN102712591A (zh) 2012-10-03
EP2448922A1 (en) 2012-05-09
US20170247329A1 (en) 2017-08-31
CL2012000009A1 (es) 2012-07-06
EP2448922B1 (en) 2014-08-20

Similar Documents

Publication Publication Date Title
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
EP2438246A4 (en) CONSTRUCTION ASPECTS
ZA201200127B (en) Fluorinated aminotriazole derivatives
EP2515713A4 (en) STABILIZATION OF OBJECTS
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
EP2515709A4 (en) STABILIZATION OF OBJECTS
HK1160925A1 (zh) 組織蛋白酶 的用途
EP2408950A4 (en) ELECTRO-RECOVERY OF METALS
GB2468936B (en) Chlorination of sucrose-6-esters
EP2501803A4 (en) PROCESS FOR PLURIPOTENZINTENSIVATION
HK1173139A1 (en) Fluorinated derivatives of 3-hydroxypyridin-4-ones 3--4-
GB0922023D0 (en) Preparation of n-monofluoroalkyl compounds
HK1142220A2 (en) Leg of tripod
EP2404891A4 (en) PROCESS FOR THE PREPARATION OF ACYLBENZENES
EP2331490A4 (en) PREPARATION OF DIBUTOXYMETHANE
EP2459540A4 (en) PREPARATION OF FIPAMEZOLE
TWM372743U (en) Improved structure of Kendama
TWM365675U (en) Improved structure of teapoy
EP2404608A4 (en) COMBINATION USE OF CHOLESTANOL DERIVATIVE
IL243319A0 (en) Intermediates of teroarylpiperidine and piperazine derivatives
GB2464599B (en) Attachment of can ends
TWM374127U (en) Structure of three-string Huqin
TWM372203U (en) Structure of goggles
GB0903773D0 (en) Works of art

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200701